At Work With: Lisa Adler

Lisa Adler
Lisa Adler

LISA ADLER
VP, corporate communications,Millennium

What was your biggest break?

I was very fortunate to start off at two wonderful PR agencies in NYC (MS&L and Porter/Novelli) and given the opportunity to work on several new product launches.

What's the best and/or worst part of your job?

One of the many highlights of my position is being able to interact with patients and their families.

Who is the person you admire most in your area of work?

I had the privilege of working side-by-side with Millennium's former CEO, Dr. Deborah Dunsire, for eight years.

What's the view like from your office/work area?

From my office I can see some of the buildings on the MIT campus.

What are your favorite industry-related Web sites?

MyMultipleMyeloma.com is one of my favorites because it is a resource of information and hope. I am awfully proud of Millennium's involvement in its development.

Where will you be in five years?

I love working in this industry and the role I play at Millennium, and envision continuing along a similar path.

You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.